![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Clover Biopharmaceuticals Gets $66 Million from CEPI for COVID-19 Vaccine Trial
Clover Biopharmaceuticals Gets $66 Million from CEPI for COVID-19 Vaccine Trial
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
July 9, 2020
Chinese drugmaker Clover Biopharmaceuticals received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its COVID-19 vaccine candidate.
The funding will support early testing and the preparation of sites for a global efficacy trial. CEPI anticipates providing more funding if the early stage clinical development is successful.
Clover’s S-Trimer is “a promising vaccine candidate with the potential to be scaled up to produce hundreds of millions or even one billion doses per year,” said CEPI’s CEO Richard Hatchett.
Upcoming Events
-
21Oct